Antibacterial peptides(Antibacterial peptides)

概要

基本信息

药物类型

合成多肽

别名-

靶点-

作用机制-

治疗领域

感染

在研适应症-

非在研适应症

革兰氏阴性菌感染革兰氏阳性细菌感染

原研机构

University of British Columbia

在研机构-

非在研机构

University of British ColumbiaAdvanced Life Sciences Holdings, Inc.

最高研发阶段终止临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

3

项与 Antibacterial peptides 相关的临床试验

IRCT20181229042160N4 / Recruiting早期临床1期IIT

Safety evaluation of eye drops containing antibacterial peptides in the treatment of infectious bacterial keratitis

开始日期2024-01-21

申办/合作机构-

ChiCTR2300075007 / Suspended临床1期IIT

The clinical effect of BOP toothpaste containing antibacterial peptides on inhibiting dental plaque, reducing gingival inflammation, anti-dental calculus, relieving tooth sensitivity, and anti-halitosis was studied

开始日期2023-08-15

申办/合作机构-

ChiCTR2300073816 / Suspended临床1期IIT

BOP containing antibacterial peptides against halitosis mouthwashes: a clinical effect assessment

开始日期2023-07-31

申办/合作机构-

100 项与 Antibacterial peptides 相关的临床结果

登录后查看更多信息

100 项与 Antibacterial peptides 相关的转化医学

登录后查看更多信息

100 项与 Antibacterial peptides 相关的专利（医药）

登录后查看更多信息

127

项与 Antibacterial peptides 相关的文献（医药）

2024-09-01·Animal Bioscience

Dietary apidaecin Api-PR19 addition enhances growth performance by regulating gut health and microbiota in broilers

Article

作者: Wang, Xinrui ; Wang, Chenxu ; Liu, Rui ; Yang, Xiaojun ; Zhang, Lixin ; Min, Jiyang

Objective: This study investigated the effects of Apidaecin Api-PR19 as feed additive on growth performance, intestinal health, and small intestinal microbiota of broilers.Methods: A total of 360 1-d-old Arbor Acres broilers were randomly assigned to 3 groups with 6 replicates including control group with basal diet (CON), antibiotic growth promotor group with basal plus 10 mg/kg colistin sulfate and 50 mg/kg roxarsone (AGP), and antibacterial peptide group with basal diet plus 330 mg/kg Apidaecin Api-PR19 (ABP). The trial lasted 35 d.Results: Results showed that dietary Api-PR19 addition increased (p<0.05) the average daily feed intake, average daily gain and decreased (p<0.05) feed conversion ratio (FCR) during 1 to 21 d compared with the CON group. The digestibility of dry matter and crude protein were higher in AGP and ABP groups (p<0.05) where greater trypsin activity was detected in duodenum (p<0.05). The ratio of villus height to crypt depth (V/C) in duodenum and jejunum was increased at 35 d when broilers were given diets with ABP or AGP (p<0.05). Besides, ABP treatments up-regulated (p<0.05) the mRNA expression of EAAT3, GLUT2, ZO-1, and Claudin-1 in duodenum of broilers at 35 d of age. The results of immunohistochemistry showed that ABP treatment significantly increased (p<0.05) duodenal secretory immunoglobulin A (sIgA) content. In addition, 16S rRNA gene sequencing revealed that there were differences in the intestinal microbiota diversity and composition among three groups. Notably, the linear discriminant analysis effect size showed that p_Firmicutes, g_Enterococcus, g_Carnobacterium, g_Kitasatospora, and g_Acidaminococcus were dominant in ABP group. Redundancy analysis showed that these changes in gut microbiota in ABP group had correlation with growth performance, intestinal morphology, and content of sIgA.Conclusion: In general, these results indicated that dietary 330 mg/kg Apidaecin Api-PR19 supplementation promoted growth performance of broilers by improving intestinal development, nutrients absorption, immune function and modulating intestinal microbiota.

2024-07-01·Molecular Nutrition & Food Research

Potential Impact of Bioactive Peptides from Foods in the Treatment of Hypertension

Review

作者: Orenes‐Piñero, Esteban ; Marín, Francisco ; Ichim, Natalia

ScopeHigh blood pressure (BP) is the main preventable risk factor for cardiovascular diseases (CVDs). Much research is aimed at finding natural alternatives to control or prevent hypertension (HT), since some hypertensive patients do not respond to current pharmacological treatments or show undesirable side effects.Methods and resultsForty relevant articles have been selected from various scientific literature databases. The results reveal that angiotensin‐converting enzyme (ACE) inhibition is the most reported mechanism of action of antihypertensive peptides. The active peptides have a great variety of origins. Biopeptides with a molecular weight of <3 kDa, short chain <20 amino acids, and a hydrophobic amino acid sequence at the C‐ and N‐terminus exhibit higher antihypertensive activity. They also show good stability to enzymatic hydrolysis and gastrointestinal digestion, and no toxicity. To determine antihypertensive effectiveness, in vitro and in vivo animal studies are the most frequent developed, with few in silico studies and only one human clinical trial.ConclusionThere is interesting potential for antihypertensive peptides as promising natural candidates for the development of functional foods, nutraceuticals and drugs for preventive or therapeutic treatment of hypertension. The aim of this review is to study the role of food‐derived bioactive peptides in HT.

2023-11-01·Biomaterials

Binding-induced fibrillogenesis peptide inhibits RANKL-mediated osteoclast activation against osteoporosis

Article

作者: Yu, Long ; Liang, Qi-Lin ; Ding, Meng-Ru ; Wang, Hao ; Zhang, Kuo ; Wang, Lei ; Cui, Xu ; Qi, Gao-Feng ; Xu, Huan-Ge ; Li, Yu-Ting

Osteoporosis is primarily driven by an imbalance between bone resorption and formation, stemming from enhanced osteoclast activity during bone remodeling. At the crux of this mechanism lies the pivotal RANK-RANKL-OPG axis. In our study, we designed two binding-induced fibrillogenesis (BIF) peptides, namely BIFP and BIFY, targeting RANK and RANKL, respectively. These BIF peptides, with distinct hydrophilic and hydrophobic characteristics, assemble into nanoparticles (NPs) in aqueous solution. Through specific ligand-receptor interactions, these NPs efficiently target and bind to specific proteins, resulting in the formation of fibrous networks that effectively inhibit the RANK-RANKL associations. Experiments have confirmed the potent inhibitory effects of peptides on both osteoclast differentiation and function. Compared with the +RANKL controls, BIFP and BIFY demonstrated a more remarkable reduction in tartrate resistant acid phosphatase (TRAP)-positive cells, achieving an impressive decline of 82.8% and 70.7%, respectively. Remarkably, the administration of BIFP led to a substantial reduction in bone resorption pit area by 17.4%, compared to a significant increase of 92.4% in the +RANKL groups. In vivo experiments on an ovariectomized mouse model demonstrated that the BIFP treated group exhibited an impressive 2.6-fold elevation in bone mineral density and an astounding 4.0-fold enhancement in bone volume/total volume as against those of the PBS-treated group. Overall, BIF peptides demonstrate remarkable abilities to impede osteoclast differentiation, presenting promising prospects for the treatment of osteoporosis.

100 项与 Antibacterial peptides 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
革兰氏阴性菌感染	临床前	-	Advanced Life Sciences Holdings, Inc.	-
革兰氏阴性菌感染	临床前	-	University of British Columbia	-
革兰氏阳性细菌感染	临床前	-	Advanced Life Sciences Holdings, Inc.	-
革兰氏阳性细菌感染	临床前	-	University of British Columbia	-